SAMRAT SARKAR, AMITY UNIVERSITY KOLKATA
Where the entire world is trying to find a way out of this pandemic situation, Bharat Biotech with collaborated with Washington University School of Medicine in St. Louis have gone for another massive bang on the pandemic by trying a new novel chimp-adenovirus, a single-dose intranasal vaccine for Covid-19 using the indigenous Covaxin, with tie-ups with ICMR-NIV.
According to the pact, Bharat Biotech can distribute this vaccine on success to the global market except for the USA, Europe and Japan. Although the Phase 1 trials will be done abroad, on approval India will conduct the trials in Hyderabad.
An estimate of over 1 Billion doses of this vaccine is made by Bharat Biotech and, have also started a reduce in the use of medicines and syringes. Causing an effective impact on humanity in near future, scientists have claimed it to be much more effective than the other vaccines, as it can attain an effective immunization to the body, causing the cells of the nasal and throat to be the primary barriers for any further invasions.
Suggested Read
https://timesofindia.indiatimes.com/business/india-business/bharat-biotech-in-pact-with-wusm-for-intranasal-chimp-adenovirus-covid-19-vaccine/articleshow/78269876.cms
Citation: Contributions of Dr David T Curiel, Dr Krishna Ella
Paraphrase: Bharat Biotech’s new collab with USA as a better enforcement strategy for Covaxin
For more updates, please visit – https://bioxone.in//
????????????????????????